Aldevron News

Jennifer Meade Appointed President of Integrated DNA Technologies and Aldevron

June 22, 2026 / by Aldevron

Proven leader to drive sharper execution and faster breakthroughs across research, diagnostics, and advanced therapeutics

Integrated DNA Technologies (IDT), a global leader in genomics, and Aldevron, a global leader in the production of DNA, RNA and protein, today announced that Jennifer Meade has been appointed president of IDT and Aldevron. As head of Aldevron since 2023, Meade expands her leadership to both organizations, guiding a coordinated approach that strengthens scientific expertise, manufacturing capabilities and operational execution, providing customers with robust genomic tools to move from discovery to commercial-scale impact with speed and confidence.

“The opportunity to serve customers across the genomics landscape is clear,” said Meade. “By focusing on what matters most—speed, reliability and unmatched scientific depth—we can help clients fast-track their innovations, accelerate progress, and deliver meaningful outcomes across their key research, diagnostic, and therapeutic programs.”

Leadership to advance the next era of genomic innovation
IDT and Aldevron play critical roles in enabling applications shaping modern medicine, from cancer to rare diseases. Under Meade’s leadership, both organizations will continue to scale their differentiated capabilities to meet growing demand for advanced genomic solutions. In precision oncology, IDT’s leadership in next generation sequencing (NGS) and continued investments in synthesis capacity and transformative manufacturing technologies support a substantial share of innovators advancing research in MRD and multi-early cancer detection. At the same time, Aldevron’s expertise in process development and CGMP manufacturing provides the quality, consistency, and regulatory rigor required to deliver advanced therapies to patients.

Meade brings more than 20 years of healthcare leadership experience and a strong track record of driving innovation and operational performance. Prior to Aldevron, she spent 16 years at a global medical technology company developing technologies to detect, diagnose and treat women’s health conditions. Her appointment reflects continued focus on strong leadership, disciplined execution, and meaningful customer impact.

Disclaimer: Integrated DNA Technologies (IDT) offers both Research Use Only (RUO) and In Vitro Diagnostic (IVD) products; Aldevron provides Research Grade (RG) and Current Good Manufacturing Practice (CGMP) products. RUO and RG products are intended for research use only and are not for use in diagnostic or therapeutic procedures. IVD and CGMP products are intended for diagnostic or clinical applications as specified in product documentation. References to clinical, diagnostic, or therapeutic impact pertain only to products with appropriate regulatory clearance. Purchasers are responsible for ensuring appropriate use and compliance with applicable regulations. For further information about product classifications and intended uses, please contact our regulatory affairs team or refer to product documentation.

Media Contacts

Integrated DNA Technologies	Aldevron
Kristina Sarenas Director, Public Relations ksarenas@idtdna.com (714) 213-9468	Ellen Shafer Senior Director of Communications ellen.shafer@aldevron.com (701) 219-0333

About IDT
Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT), a Danaher company, has evolved from an oligo manufacturer to a leading genomics solutions provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.

For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, YouTube, Instagram and Bluesky.

About Aldevron
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us.